In the context of Alzheimer’s disease, most known factors would argue that, even though CK2 expression was shown to be reduced, a further inhibition of CK2 through pharmacological means may be beneficial in reducing the burden of hyperphosphorylated tau and neurofibrillary tangles. Here, MAPT is linked to Alzheimer disease.